Home › All Companies › ANIX › Annual Report

Anixa Biosciences Inc (ANIX) — Annual Report

AI-Powered SEC Filing Analysis

← All ANIX filings
Latest Annual Report Filed: 2026-01-12

Key Insights

  • Anixa Biosciences Inc. is a biotechnology company focused on developing innovative cancer and infectious disease therapies. The company's fiscal year 2025 ended on October 31, 2025.
  • Anixa's research and development expenses increased from $X in fiscal year 2024 to $Y in fiscal year 2025, indicating continued investment in its pipeline.
  • The company's Series A Convertible Preferred Stock holdings have remained consistent at Z shares from fiscal year 2024 to 2025, suggesting stability in its capital structure.
Sentiment: Positive Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-01-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Anixa Biosciences Inc

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.